Home › Prostate Cancer › NCT00923221
Collection of Blood From Patients With Prostate Cancer
Who can join
Ages 18 and older · Men
Full eligibility criteria
* INCLUSION CRITERIA: Individuals 18 years of age and older are eligible. Individuals with a diagnosis of prostate cancer are eligible. EXCLUSION CRITERIA: Children are not eligible.
About the study
Background:
* It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role. * Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene. * Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others.
Objectives:
-To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state.
Eligibility:
-All participants participating in NCI prostate cancer protocols.
Design:
* Participants with prostate cancer are evaluated in the NCI s Medical Oncology Clinic. * Blood samples are collected at the initial visit or at follow-up visits. * DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines. * Gene variations are correlated with prostate cancer prognosis and prognostic indicators.
Sponsor: National Cancer Institute (NCI) · Participants: 1,000 · Started: Feb 28, 2007
Contact the study team
- Paula A Carter, R.N. · Phone: (240) 858-3191
- William D Figg, Pharm.D. · Phone: (240) 760-6179
Official record on ClinicalTrials.gov — NCT00923221
Locations in the U.S.
| Maryland | National Institutes of Health Clinical Center, Bethesda |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.